Pre-texto : Una aproximación a El asco

En distintas narraciones de Castellanos Moya se lee lo que una parte de la crítica ha llamado el discurso cínico: en una puesta de escena postrevolucionaria el autor se vale de sus personajes para crear un discurso descarnado, apátrida y contestatario que trasciende las nociones de nación y se encarna en una serie de costumbres y ritos culturales. Tal es el caso del personaje principal de la novela El asco. Thomas Bernhard en San Salvador (un migrante que vuelve por poco tiempo a San Salvador): sus opiniones limitan con la desmesura; en dicha desmesura, la violencia de la voz parece sobrepasar la noción de cinismo para desbordar en un discurso que pareciera erigirse violentamente en sí mismo. Analizar los bordes del texto, así como los modos discursivos de los que se vale el autor para trabajar la violencia en el lenguaje, permite rastrear el modo en que se dan los acondicionamientos narrativos para tratar de señalar los procedimientos utilizados. Para ello me remito primero a un cuento "inaugural" de la narrativa del Castellano Moya, para después fijar como, en un giro que tiende a traspasar los límites de la "ficción", el autor propone en El asco. Thomas Bernhard en San Salvador otra manera de concebir su narrativa (que ha sido caracterizada por el trabajo con la violencia), y como a su vez opaca el trabajo entre imaginación y creación, que son constantes en la obra del salvadoreño, para trabajar con la oralidad y cierta realidad política de posguerra de su país. Para ello propongo algunas reflexiones que se vinculan a la creación de caracteres y tipos narrativos, enfatizando el análisis de un discurso que pareciera en primera persona, así como la construcción del verosímil y la problematización del suceder narrativo desde el exergo mismo

Pre-texto : Una aproximación a El asco

En distintas narraciones de Castellanos Moya se lee lo que una parte de la crítica ha llamado el discurso cínico: en una puesta de escena postrevolucionaria el autor se vale de sus personajes para crear un discurso descarnado, apátrida y contestatario que trasciende las nociones de nación y se encarna en una serie de costumbres y ritos culturales. Tal es el caso del personaje principal de la novela El asco. Thomas Bernhard en San Salvador (un migrante que vuelve por poco tiempo a San Salvador): sus opiniones limitan con la desmesura; en dicha desmesura, la violencia de la voz parece sobrepasar la noción de cinismo para desbordar en un discurso que pareciera erigirse violentamente en sí mismo. Analizar los bordes del texto, así como los modos discursivos de los que se vale el autor para trabajar la violencia en el lenguaje, permite rastrear el modo en que se dan los acondicionamientos narrativos para tratar de señalar los procedimientos utilizados. Para ello me remito primero a un cuento "inaugural" de la narrativa del Castellano Moya, para después fijar como, en un giro que tiende a traspasar los límites de la "ficción", el autor propone en El asco. Thomas Bernhard en San Salvador otra manera de concebir su narrativa (que ha sido caracterizada por el trabajo con la violencia), y como a su vez opaca el trabajo entre imaginación y creación, que son constantes en la obra del salvadoreño, para trabajar con la oralidad y cierta realidad política de posguerra de su país. Para ello propongo algunas reflexiones que se vinculan a la creación de caracteres y tipos narrativos, enfatizando el análisis de un discurso que pareciera en primera persona, así como la construcción del verosímil y la problematización del suceder narrativo desde el exergo mismo

Pre-texto : Una aproximación a El asco

En distintas narraciones de Castellanos Moya se lee lo que una parte de la crítica ha llamado el discurso cínico: en una puesta de escena postrevolucionaria el autor se vale de sus personajes para crear un discurso descarnado, apátrida y contestatario que trasciende las nociones de nación y se encarna en una serie de costumbres y ritos culturales. Tal es el caso del personaje principal de la novela El asco. Thomas Bernhard en San Salvador (un migrante que vuelve por poco tiempo a San Salvador): sus opiniones limitan con la desmesura; en dicha desmesura, la violencia de la voz parece sobrepasar la noción de cinismo para desbordar en un discurso que pareciera erigirse violentamente en sí mismo. Analizar los bordes del texto, así como los modos discursivos de los que se vale el autor para trabajar la violencia en el lenguaje, permite rastrear el modo en que se dan los acondicionamientos narrativos para tratar de señalar los procedimientos utilizados. Para ello me remito primero a un cuento "inaugural" de la narrativa del Castellano Moya, para después fijar como, en un giro que tiende a traspasar los límites de la "ficción", el autor propone en El asco. Thomas Bernhard en San Salvador otra manera de concebir su narrativa (que ha sido caracterizada por el trabajo con la violencia), y como a su vez opaca el trabajo entre imaginación y creación, que son constantes en la obra del salvadoreño, para trabajar con la oralidad y cierta realidad política de posguerra de su país. Para ello propongo algunas reflexiones que se vinculan a la creación de caracteres y tipos narrativos, enfatizando el análisis de un discurso que pareciera en primera persona, así como la construcción del verosímil y la problematización del suceder narrativo desde el exergo mismo

Q. Asco. Pediani In Ciceronis orationes commentarii atq[ue] Georgius Trapezuntius, De artificio Ciceroniae orationis Pro. Q. Ligario : nuper maxima diligentia excuti.

Edit16,

Predicting fitness for chemotherapy in older cancer patients

Background: The Vulnerable Elders Survey-13 (VES-13) is increasingly used to screen for older patients who can proceed to intensive chemotherapy without further comprehensive assessment. This study compared the VES-13 determination of fitness for treatment with the oncologist's assessments of fitness. Method: Sample: Consecutive series of solid tumour patients ≥65 years (n=175; M=72; range=65-86) from an Australian cancer centre. Patients were screened with the VES-13 before proceeding to usual treatment. Blinded to screening, oncologists concurrently predicted patient fitness for chemotherapy. A sample of 175 can detect, with 90% power, kappa coefficients of agreement between VES-13 and oncologists’ assessments >0.90 ("almost perfect agreement"). Separate backward stepwise logistic regression analyses assessed potential predictors of VES-13 and oncologists’ ratings of fitness. Results: Kappa coefficient for agreement between VES-13 and oncologists’ ratings of fitness was 0.41 (p<0.001). VES-13 and oncologists’ assessments agreed in 71% of ratings. VES-13 sensitivity = 83.3%; specificity = 57%; positive predictive value = 69%; negative predictive value = 75%. Logistic regression modelling indicated that the odds of being vulnerable to chemotherapy (VES-13) increased with increasing depression (OR=1.42; 95% CI: 1.18, 1.71) and decreased with increased functional independence assessed on the Bartel Index (OR=0.82; CI: 0.74, 0.92) and Lawton instrumental activities of daily living (OR=0.44; CI: 0.30, 0.65); RSquare=.65. Similarly, the odds of a patient being vulnerable to chemotherapy, when assessed by physicians, increased with increasing age (OR=1.15; CI: 1.07, 1.23) and depression (OR=1.23; CI: 1.06, 1.43), and decreased with increasing functional independence (OR=0.91; CI: 0.85, 0.98); RSquare=.32. Conclusions: Our data indicate moderate agreement between VES-13 and clinician assessments of patients’ fitness for chemotherapy. Current ‘one-step’ screening processes to determine fitness have limits. Nonetheless, screening tools do have the potential for modification and enhanced predictive properties in cancer care by adding relevant items, thus enabling fit patients to be immediately referred for chemotherapy.

A prática e a representação social do tabagismo entre fumantes, ex-fumantes e não fumantes

Atualmente o tabagismo é considerado pela Organização Mundial da Saúde (OMS) como um fator de risco à vida a ser combatido com alta prioridade. No entanto, um processo maciço de propaganda e marketing parece ter sido historicamente decisivo para dar à prática de fumar uma representação positiva, através de uma associação sistemática entre o consumo de derivados do tabaco e o ideal de auto-imagem, como beleza, sucesso, saúde e liberdade. Essa transformação da imagem do cigarro de símbolo de status e saúde para uma séria doença a ser combatida evidencia a importância de analisar o tabagismo como um fenômeno psicossocial. O objetivo geral desta investigação consiste, portanto, em analisar comparativamente as representações sociais acerca do tabagismo construídas por grupos de indivíduos que se incluam diferencialmente nas condições de fumantes, ex-fumantes e não-fumantes. A pesquisa foi realizada com uma amostra de 500 (quinhentos) participantes residentes no Estado do Rio de Janeiro, de ambos os sexos, podendo pertencer às categorias de fumantes, ex-fumantes e não-fumantes. A coleta de dados foi realizada por meio eletrônico, através da aplicação de um questionário, que em parte focaliza os dados sóciodemográficos dos participantes e, em outra, apresenta questões abertas e fechadas, incorporando ainda uma tarefa de evocação livre ante o termo indutor tabagismo ou prática de fumar. Os resultados da análise estrutural da representação social do tabagismo possibilitou verificar uma unanimidade quanto à significação controversa que é atribuída a ele. De um lado, verificam-se dimensões negativas desta prática, que são objetivadas pelas implicações e repercussões na saúde dos fumantes ativos e passivos e, por outro lado, existem as dimensões positivas, que representam as funções sociais do tabagismo, e as sensações prazerosas que ele provoca nos fumantes. Observa-se o processo de construção de uma nova representação social do tabagismo, onde é estabelecida uma conexão entre uma velha representação do tabagismo enquanto hábito de vida, estilo de vida, com uma nova representação, o tabagismo como vício/dependência, criando novos significados e imagens do objeto. Para concluir, vale ressaltar que as representações sociais dos ex-fumantes e dos não-fumantes mostraram-se bastantes próximas, ressaltando essencialmente os aspectos negativos do tabagismo, enquanto que a dos fumantes diferenciam-se um pouco ao apresentar elementos como prazer. Mas de modo geral, as representações não mostraram-se tão distintas, revelando que os próprios fumantes vivenciam uma relação muito antagônica com o tabagismo, manifestando em diversos momentos vontade de tornarem-se ex-fumantes. Parece que a representação do tabagismo como um hábito glamoroso não mais existe e que de fato a política de controle a ele vem obtendo êxito com suas medidas restritivas o que é algo extremamente positivo para nossa sociedade do ponto de vista da saúde pública. No entanto, na esfera social, parece necessário que essa atmosfera de temor e asco envolta no tabagismo seja pensada e refletida, para que não resulte em discriminação social com os tabagistas, tornando-os novamente vítima, mas de uma nova situação social

Malignant pleural mesothelioma: current treatments and emerging drugs

Background: Malignant pleural mesothelioma (MPM) is an uncommon disease whose incidence is increasing worldwide over the past 30 years. Surgical resection and radiotherapy represent the standard treatment in patient with resectable MPM. Chemotherapy is also necessary to reduce incidence of distant metastases, but the optimal setting of treatment (neoadjuvant, adjuvant and intrapleural) is not clarified. For the patients with unresectable MPM, the combination cisplatin and pemetrexed or ralitrexed is the standard treatment as supported by a Phase III study. Better understanding of molecular pathways involved in MPM has enabled inclusion of new drugs targeted against pathways responsible for proliferation, cell survival and angiogenesis. Objective: This review discusses the current treatment option, the specific signal pathways activated in MPM and the novel agents under evaluation in clinical trials. Methods: We use for this article abstracts, papers, oral presentations from ASCO and the website http://www.clinical-trials.gov. Results/conclusion: This review summarizes the activity of chemotherapy and of new agents under evaluation in clinical trials. The better understanding of molecular pathways activated in MPM will hopefully provide new therapeutic options for these patients in the future.

MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.

Background: RAS is mutated (RASMT) in ~55% of mCRC, and phase III studies have shown that patients harbouring RAS mutations do not benefit from anti-EGFR MoAbs. In addition, ~50% of RAS Wild Type (RASWT) will not benefit from the addition of an EGFR MoAb to standard chemotherapy. Hence, novel treatment strategies are urgently needed for RASMT and > 50% of RASWT mCRC patients. c-MET is overexpressed in ~50-60%, amplified in ~2-3% and mutated in ~3-5% of mCRC. Recent preclinical studies have shown that c-MET is an important mediator of resistance to MEK inhibitors (i) in RASMT mCRC, and that combined MEKi/METi resulted in synergistic reduction in tumour growth in RASMT xenograft models (1). A number of recent studies have highlighted the role of c-MET in mediating primary/secondary resistance to anti-EGFR MoAbs in mCRC, suggesting that patient with RASWT tumours with aberrant c-MET (RASWT/c-MET+) may benefit from anti-c-MET targeted therapies (2). These preclinical data supported the further clinical evaluation of combined MEKi/METi treatment in RASMT and RASWT CRC patients with aberrant c-MET signalling (overexpression, amplification or mutation; RASWT/c-MET+). Methods: MErCuRIC1 is a phase I combination study of METi crizotinib with MEKi PD-0325901. The dose escalation phase, utilizing a rolling six design, recruits 12-24 patients with advanced solid tumours and aims to assess safety/toxicity of combination, recommended phase II (RPII) dose, pharmacokinetics (PK) and pharmacodynamics (PD) (pERK1/2 in PBMC and tumour; soluble c-MET). In the dose expansion phase an additional 30-42 RASMT and RASWT/c-MET mCRC patients with biopsiable disease will be treated at the RPII dose to further evaluate safety, PK, PD and treatment response. In the dose expansion phase additional biopsy and blood samples will be obtained to define mechanisms of response/resistance to crizotinib/PD-0325901 therapy. Enrolment into the dose escalation phase began in December 2014 with cohort 1 still ongoing. EudraCT registry number: 2014-000463-40. (1) Van Schaeybroeck S et al. Cell Reports 2014;7(6):1940-55; (2) Bardelli A et al. Cancer Discov 2013;3(6):658-73. Clinical trial information: 2014-000463-40.

The role of JAK1/2-STAT3 as acute resistance mechanism to MEK inhibition in BRAF-mutant colorectal cancer cell lines.

Background: Oncogenic mutations in BRAF occur in 8% of patients with advanced colorectal cancer (CRC) and have been shown to correlate with poor prognosis. In contrast to BRAF mutant (MT) melanoma, where the BRAF inhibitor Vemurafenib (PLX4032) has shown significant increases in response rates and overall survival, only minor responses to Vemurafenib treatment have been reported in BRAFMT CRC. Clear understanding of the vulnerabilities of BRAFMT CRC is important, and identification of druggable targets uniquely required by BRAFMT CRC tumours has the potential to fill a gap in the therapeutic armamentarium of advanced CRC. The aim of this study was to identify novel resistance mechanisms to MEK inhibition in BRAFMT CRC. Methods: Paired BRAFMT/WT RKO and VACO432 CRC cells and non-isogenic BRAFMT LIM2405, WiDR, HT-29 and COLO205 CRC cells were used. Changes in protein expression/activity were assessed by Western Blotting. Interactions between MEK1/2 and JAK1/2 or c-MET inhibition were assessed using the MTT cell viability assays and Flow Cytometry. Apoptosis was measured using Western Blotting for PARP, cleaved caspase 3, 8 and 9, and caspase 3/7 and 8 activity assays. Results: Treatment with MEK1/2 inhibitors AZD6244, trametinib, UO126 and PD98059 resulted in acute increases in STAT3 activity in the BRAFMT RKO and VACO432 cells but not in their BRAFWT clones and this was associated with increases in JAK2 activity. Inhibition of JAK/STAT3 activation using gene specific siRNA or small molecule inhibitors TG101348 or AZD1480, abrogated this survival response and resulted in synergy and significant increases in cell death when combined with MEK1/2 inhibitors AZD6244 or trametinib in BRAFMT CRC cells. The RTK c-MET is activated upstream of STAT3 following MEK1/2 inhibition. Inhibition of c-MET and MEK1/2, using pharmacological inhibitors (crizotinib and AZD6244), results in synergy and increased cell death in BRAFMT CRC cells. Conclusions: We have identified JAK/STAT3 activation as an important escape mechanism for BRAFMT CRC following MEK1/2 inhibition in vitro. Combinations of JAK/MEKi or MET/MEKi can be a potential novel treatment strategy for poor prognostic BRAFMT advanced CRC patients.

The prognostic and therapeutic value of EpHA2 in early colorectal cancer (CRC).

Background: EpHA2 is a 130 kD transmembrane glycoprotein belonging to ephrin receptor subfamily and involved in angiogenesis/tumour neovascularisation. High EpHA2 mRNA level has recently been implicated in cetuximab resistance. Previously, we found high EpHA2 levels in a panel of invasive colorectal cancer (CRC) cells, which was associated with high levels of stem-cell marker CD44. Our aim was to investigate the prognostic value of EpHA2 and subsequently correlate expression levels to known clinico-pathological variables in early stage CRC. Methods: Tissue samples from 509 CRC patients were analysed. EpHA2 expression was measured using IHC. Kaplan-Meier graphs were used. Univariate and multivariate analyses employed Cox Proportional Hazards Ratio (HR) method. A backward selection method (Akaike’s information criterion) was used to determine a refined multivariate model. Results: EpHA2 was highly expressed in CRC adenocarcinoma compared to matched normal colon tissue. In support of our preclinical invasive models, strong correlation was found between EpHA2 expression and CD44 and Lgr5 staining (p<0.001). In addition, high EpHA2 expression significantly correlated with vascular invasion (p=0.03).HR for OS for stage II/III patients with high EpHA2 expression was 1.69 (95%CI: 1.164-2.439; p=0.003). When stage II/III was broken down into individual stages, there was significant correlation between high EpHA2 expression and poor 5-years OS in stage II patients (HR: 2.18; 95%CI: 1.28-3.71; p=0.005).HR in the stage III group showed a trend to statistical significance (HR: 1.48; 95%CI=0.87-2.51; p=0.05). In both univariate and multivariate analyses of stage II patients, high EpHA2 expression was the only significant factor and was retained in the final multivariate model. Higher levels of EpHA2 were noted in our RAS and BRAF mutant CRC cells, and silencing EpHA2 resulted in significant decreases in migration/invasion in parental and invasive CRC sublines. Correlation between KRAS/NRAS/BRAFmutational status and EpHA2 expression in clinical samples is ongoing. Conclusions: Taken together, our study is the first to indicate that EpHA2 expression is a predictor of poor clinical outcome and a potential novel target in early stage CRC.

Construção de um sensor eletroquímico molecularmente impresso para monitorização do cancro da mama

O Cancro da mama é uma doença cuja incidência tem vindo a aumentar de ano para ano e além disso é responsável por um grande número de mortes em todo mundo. De modo a combater esta doença têm sido propostos e utilizados biomarcadores tumorais que permitem o diagnóstico precoce, o acompanhamento do tratamento e/ou a orientação do tipo tratamento a adotar. Atualmente, os biomarcadores circulantes no sangue periférico recomendados pela Associação Americana de Oncologia Clinica (ASCO) para monitorizar os pacientes durante o tratamento são o cancer antigen 15-3 (CA 15-3), o cancer antigen 27.29 (CA 27.29) e o cancer embryobic antigen (CEA). Neste trabalho foi desenvolvido um sensor eletroquímico (voltamétrico) para monitorizar o cancro da mama através da análise do biomarcador CA 15-3. Inicialmente realizou-se o estudo da adsorção da proteína na superfície do elétrodo para compreender o comportamento do sensor para diferentes concentrações. De seguida, estudaram-se três polímeros (poliaminofenol, polifenol e polifenilenodiamina) e selecionou-se o poliaminofenol como o polímero a utilizar, pois possuía a melhor percentagem de alteração de sinal. Após a seleção do polímero, este foi depositado na superfície do elétrodo por eletropolimerização, formando um filme polimérico molecularmente impresso (MIP) à volta da proteína (molde). Posteriormente, foram analisados cinco solventes (água, mistura de dodecil sulfato de sódio e ácido acético, ácido oxálico, guanidina e proteinase K) e o ácido oxálico revelou ser mais eficaz na extração da proteína. Por último, procedeu-se à caraterização do sensor e analisou-se a resposta analítica para diferentes concentrações de CA 15-3 revelando diferenças claras entre o NIP (polímero não impresso) e o MIP.

Device-specific weighted T-score for two quantitative ultrasounds: operational propositions for the management of osteoporosis for 65 years and older women in Switzerland.

The World Health Organization (WHO) criteria for the diagnosis of osteoporosis are mainly applicable for dual X-ray absorptiometry (DXA) measurements at the spine and hip levels. There is a growing demand for cheaper devices, free of ionizing radiation such as promising quantitative ultrasound (QUS). In common with many other countries, QUS measurements are increasingly used in Switzerland without adequate clinical guidelines. The T-score approach developed for DXA cannot be applied to QUS, although well-conducted prospective studies have shown that ultrasound could be a valuable predictor of fracture risk. As a consequence, an expert committee named the Swiss Quality Assurance Project (SQAP, for which the main mission is the establishment of quality assurance procedures for DXA and QUS in Switzerland) was mandated by the Swiss Association Against Osteoporosis (ASCO) in 2000 to propose operational clinical recommendations for the use of QUS in the management of osteoporosis for two QUS devices sold in Switzerland. Device-specific weighted "T-score" based on the risk of osteoporotic hip fractures as well as on the prediction of DXA osteoporosis at the hip, according to the WHO definition of osteoporosis, were calculated for the Achilles (Lunar, General Electric, Madison, Wis.) and Sahara (Hologic, Waltham, Mass.) ultrasound devices. Several studies (totaling a few thousand subjects) were used to calculate age-adjusted odd ratios (OR) and area under the receiver operating curve (AUC) for the prediction of osteoporotic fracture (taking into account a weighting score depending on the design of the study involved in the calculation). The ORs were 2.4 (1.9-3.2) and AUC 0.72 (0.66-0.77), respectively, for the Achilles, and 2.3 (1.7-3.1) and 0.75 (0.68-0.82), respectively, for the Sahara device. To translate risk estimates into thresholds for clinical application, 90% sensitivity was used to define low fracture and low osteoporosis risk, and a specificity of 80% was used to define subjects as being at high risk of fracture or having osteoporosis at the hip. From the combination of the fracture model with the hip DXA osteoporotic model, we found a T-score threshold of -1.2 and -2.5 for the stiffness (Achilles) determining, respectively, the low- and high-risk subjects. Similarly, we found a T-score at -1.0 and -2.2 for the QUI index (Sahara). Then a screening strategy combining QUS, DXA, and clinical factors for the identification of women needing treatment was proposed. The application of this approach will help to minimize the inappropriate use of QUS from which the whole field currently suffers.